About 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase (EBP) is a protein
from Homo sapiens identified by UniProt accession
Q15125, 230 residues long.
MolForge cross-references it against 0 known binders and
86 disease associations.
Target properties
| Protein name | 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase |
|---|
| UniProt accession | Q15125 |
|---|
| Gene | EBP |
|---|
| Organism | Homo sapiens |
|---|
| Length | 230 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (11)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (86)
Diseases linked to this target (Open Targets).
- X-linked dominant chondrodysplasia punctata · score 0.83
- MEND syndrome · score 0.80
- X-linked chondrodysplasia punctata 2 · score 0.74
- neurodegenerative disease · score 0.48
- forced expiratory volume · score 0.46
- lysosomal storage disease · score 0.37
- Polydactyly · score 0.37
- polydactyly · score 0.37
- connective tissue disease · score 0.31
- genetic disorder · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15125-F1 | alphafold | PREDICTED | 95.57 | — |
Amino-acid sequence (230 residues)
MTTNAGPLHP YWPQHLRLDN FVPNDRPTWH ILAGLFSVTG VLVVTTWLLS GRAAVVPLGT WRRLSLCWFA VCGFIHLVIE GWFVLYYEDL LGDQAFLSQL WKEYAKGDSR YILGDNFTVC METITACLWG PLSLWVVIAF LRQHPLRFIL QLVVSVGQIY GDVLYFLTEH RDGFQHGELG HPLYFWFYFV FMNALWLVLP GVLVLDAVKH LTHAQSTLDA KATKAKSKKN
Explore 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets